NanOlogy Reports the Completion of Patient Enrollment of LSAM-PTX in P-IIa Trial for the Treatment of Nonoperable Lung Cancer
Shots:
- The company has completed the patient enrollment in the P-IIa trial evaluating the safety and tolerability of LSAM-PTX (IT) + SoC in 18 patients with nonoperable lung cancer at four clinical sites. Prior to open enrollment, the safety assessment was completed for each of the first three patients
- The primary outcome of the trial is safety as determined by TEAEs while the secondary measures incl. plasma paclitaxel concentration, tumor response, survival, and immune response by flow cytometry analysis
- Additionally, the preliminary results showed that LSAM-PTX was well tolerated with encouraging signs of tumor and immune response. The company is expected the final results and clinical study report in Q3’23
Ref: Businesswire | Image: NanOlogy
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
